M.E. Allison & Co., Inc. Myriad Genetics Inc Transaction History
M.E. Allison & Co., Inc.
- $101 Billion
- Q1 2025
A detailed history of M.E. Allison & Co., Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, M.E. Allison & Co., Inc. holds 10,520 shares of MYGN stock, worth $78,058. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,520Holding current value
$78,058% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding MYGN
# of Institutions
226Shares Held
85.6MCall Options Held
297KPut Options Held
20.7K-
Black Rock Inc. New York, NY15.2MShares$112 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$78.6 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$41 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.35MShares$32.2 Million0.03% of portfolio
-
Glenview Capital Management, LLC New York, NY4.16MShares$30.8 Million1.44% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $598M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...